Combining the benefits of a disciplined hospital system and a leader in e-commerce, the new joint venture between Tenet and Chemdex hopes to create a differentiated offering in e-health. The new company has the ability to integrate the hospitals and suppliers Tenet/BuyPower represents, thus providing the critical mass that e-commerce companies have, until now, lacked. But company officials insist that their real advantage is that they offer a different approach to e-commerce, one that focuses on an end-to-end solution tied to the hospital's ERP system, rather than simply a web site to make ordering and inventory management more efficient.
by David Cassak
It's hard to imagine, but only a year ago, discussions of the likely impact of the Internet on the hospital...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Pharma leaders are shifting from AI pilots to enterprise-scale deployment, favoring external partnerships for efficiency gains while maintaining tight control over sensitive clinical data.
The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.
In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.
Replimune's RP1 oncolytic immunotherapy became the third regenerative medicine to receive an FDA complete response letter this month as the agency appears to re-visit previous agreements about accelerated approval.
The biotech funding landscape is undergoing a fundamental shift. With traditional VC becoming increasingly cautious and selective, industry executives are exploring new avenues for capital. Conversely, this evolution may ultimately benefit the sector's long-term sustainability.
MoonLake Immunotherapeutics is racing ahead in the biotech space with its innovative nanobody SLK and a transformative $500m non-dilutive financing deal. In this episode, its CEO and CFO discuss the company’s rapid clinical progress, financial strategy and ambitions to reshape inflammatory disease.
